Grifols, S.A.

NasdaqGS:GRFS Stock Report

Market Cap: US$6.2b

Grifols Management

Management criteria checks 3/4

Grifols' CEO is Nacho Abia Buenache, appointed in Apr 2024, has a tenure of 2.25 years. total yearly compensation is €3.52M, comprised of 56.9% salary and 43.1% bonuses, including company stock and options. directly owns 0.017% of the company’s shares, worth $1.06M. The average tenure of the management team and the board of directors is 6 years and 4.1 years respectively.

Key information

Nacho Abia Buenache

Chief executive officer

€3.5m

Total compensation

CEO salary percentage56.87%
CEO tenure2.3yrs
CEO ownership0.02%
Management average tenure6yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

Seeking Alpha • Jul 03

Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)

Summary First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian plasma platform), optimization of the U.S. collection network, and continued Biotest integration are expected to support sustainable margin expansion. Even applying a conservative valuation multiple, we see upside. Grifols' valuation is compelling. Read the full article on Seeking Alpha
Seeking Alpha • Apr 23

Grifols: A Market Setback Turns Into Buying Opportunity

Summary Grifols, a Spanish multinational specializing in plasma-derived therapies, is undervalued due to historical mismanagement but holds a strong market position with significant competitive advantages. New management has implemented an operational improvement plan, showing positive results in 2024, including record revenues, improved EBITDA margins, and increased free cash flow. Key risks include potential U.S. immigration policies affecting plasma supply and the emergence of recombinant protein substitutes, which could erode revenue by 2028. The business is poised for growth with a strategic plan targeting revenue growth, improved margins, and significant free cash flow generation, making it an attractive investment opportunity. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale

Summary Grifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company's revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Grifols' valuation is attractive, with a potential upside to €20/share, driven by EPS growth and market expansion in plasma-derived products. I maintain a "BUY" rating for Grifols, expecting a significant return on investment over the next 1-4 years. Read the full article on Seeking Alpha
Seeking Alpha • Nov 29

Grifols: More Attractive Than In A Very Long Time

Summary I don't divest unless the fundamental thesis changes; Grifols' buyout offer from Brookfield Asset Management is undervalued, so I maintain my "Buy" stance. Despite Brookfield's offer, I believe Grifols is worth more, as supported by recent 3Q24 results and the transaction committee's recommendation. The transaction committee advises against accepting the €10.5/share offer, aligning with my view that Grifols' real value is higher. This situation is instructive for valuation investors, demonstrating the importance of assessing a company's true worth beyond buyout offers. Read the full article on Seeking Alpha
Seeking Alpha • Oct 03

Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down

Summary Grifols, S.A. is undervalued and worth more than its current market valuation, making it a strong buy even without a potential Brookfield buyout. The company leads the global plasma market, with significant growth in immunoglobulin and albumin segments, and has a robust infrastructure and geographical reach. Despite facing competition and emerging technologies, Grifols' fundamentals are solid, with impressive 2024 earnings forecasts and improving margins and leverage. The lack of a dividend is a downside, but the potential for significant returns based on historical P/E ratios makes Grifols a speculative “Buy”. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Grifols: Stay On The Sidelines

Summary Grifols leverage and governance concerns are primarily addressed. The company confirms discussions around a potential combined PE/family bid offer. Still, there is a high debt and negligible FCF generation to consider. We remain neutral. Read the full article on Seeking Alpha
Seeking Alpha • May 07

Grifols: Why To Watch From The Sidelines

Summary Grifols, a major player in global plasma extraction and processing, has experienced a significant 43% decline in stock price in 2024 following a bearish report from Gotham. KPMG and the Spanish regulator have offered a more favorable perspective based on Grifols’ 2023 results, suggesting that while the company’s structure warrants caution, it is not without value. For investors seeking value, the question is: Is there enough margin of safety? A closer examination reveals that Grifols is facing several challenges compared to its competitors, compounded by debt. Read the full article on Seeking Alpha
Seeking Alpha • Mar 05

Grifols: Q4 Was Positive, Still Too Many Question Marks

Summary Grifols faces new accusations from the hedge fund Gotham City. Gotham City questions loans and outgoing flows recorded in Grifols' financial report, as well as the role of Scranton Enterprises. Grifols disclosed a lack of FCF generation in 2024. We are neutral, given a soft outlook for the current year. On a positive note, Grifols confirmed the Shanghai RAAS equity stake divestment. Read the full article on Seeking Alpha
Seeking Alpha • Jan 10

Grifols: I've Read The Short-Seller Report, And I Mostly Disagree

Summary Grifols' position in the pharma industry has dropped due to a short-seller report, causing its stock to decline. The report questions the accounting treatment of M&As and consolidation of entities in Grifols' filings. I believe that the allegations in the report are not significant enough to warrant a 20% drop in the company's stock and plans to wait for a reaction before adding more to their stake. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Nacho Abia Buenache's remuneration changed compared to Grifols's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

€415m

Dec 31 2025€4m€2m

€402m

Compensation vs Market: Nacho's total compensation ($USD4.01M) is below average for companies of similar size in the US market ($USD8.38M).

Compensation vs Earnings: Insufficient data to compare Nacho's compensation with company performance.

CEO

Nacho Abia Buenache (58 yo)

2.3yrs
Tenure
€3,517,000
Compensation

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

Leadership Team

NamePositionTenureCompensationOwnership
Jose Ignacio Abia Buenache
CEO & Director2.3yrs€3.52m0.017%
$ 1.1m
Rahul Srinivasan
Chief Financial Officer1.8yrsno data0.011%
$ 698.1k
Lluis Gomez
Senior Vice President of Strategy & COO Officeno datano datano data
Daniel Segarra
Head of Investor Relations & Sustainability and Vice Presidentno datano datano data
David Bell
Chief Corporate Affairs & Legal Officer23.5yrsno data0.0029%
$ 181.1k
Enrique de la Torre
Chief Compliance Officer7.5yrsno datano data
Montse Ribas
Chief Communications and Reputation Officer1.3yrsno data0.0025%
$ 151.6k
Camille Alpi
Chief Human Resources & Talent Officer2.4yrsno data0%
$ 0
Vicente Blanquer Torre
Chief Quality Officer33.5yrsno data0%
$ 0
Ignacio Ramal Subira
Chief Internal Audit & Enterprise Risk Manager4.5yrsno data0.0011%
$ 65.3k
Sergio Adell
President of Commercial Tech Support7.5yrsno datano data
Daniel Coit
Chief Industrial Services Officer7.5yrsno datano data
6.0yrs
Average Tenure
57yo
Average Age

Experienced Management: GRFS's management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jose Ignacio Abia Buenache
CEO & Director2.4yrs€3.52m0.017%
$ 1.1m
Paul Herendeen
Proprietary Director1.6yrs€129.00kno data
Iñigo Mardones
Independent Director11.2yrs€164.00kno data
Victor Grifols Roura
Chairman of Honourno data€129.00k0%
$ 0
Pascal Ravery
Independent Director1.6yrs€129.00kno data
Juan Twose Roura
Member of the Advisory Committee11.5yrs€380.00kno data
Raimon Grifols Roura
Vice-Chairman11.2yrs€129.00k0.0084%
$ 516.9k
Tomas Daga Gelabert
Independent External Director26.3yrs€129.00k0.045%
$ 2.7m
Víctor Grifols Deu
Proprietary Director10.2yrs€4.45m0.023%
$ 1.4m
Albert Coma-Cros
Proprietary Director2.6yrs€129.00k0.0097%
$ 597.6k
Montserrat Abellana
Independent Director4.1yrs€164.00kno data
Susana Gonzalez Rodriguez
Independent Director4.1yrs€154.00kno data
4.1yrs
Average Tenure
62yo
Average Age

Experienced Board: GRFS's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 22:14
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Grifols, S.A. is covered by 29 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBanco de Sabadell. S.A.
Luis ArredondoBanco de Sabadell. S.A.
Jaime EscribanoBanco Santander